Barinthus Biotherapeutics (BRNS) Stock Price, Quote, News & History | Benzinga

Barinthus Biotherapeutics PLC (BRNS) Stock Price, Quote, News & History

BRNSNASDAQ

Trade with Public

Trade with Public

$0.5900

-0.0099-1.65%

Last update: Aug 13, 5:04 AM

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Compare Stock Report

Key Statistics

Open

$0.59

Close

-

Volume / Avg.

251.00 / 75.64K

Day Range

$0.59 - $0.59

52 Wk Range

0.51 - 1.83

Market Cap

$24.10M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

45

Short Interest

0.18%

Days to Cover

1.82

Recent Barinthus Biotherapeutics PLC News

Why Qualcomm Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

Qualcomm shares rose 10.6% in pre-market trading after reporting better-than-expected Q2 results. Other gainers include ABTS, AKAN, VSME, OSRH, AREB, VIAV, PI, INM, and MRAM.

Avi Kapoor

US Stocks Mixed; Bank of America Earnings Top Views

Avi Kapoor

Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

Infection-Focused Barinthus Bio's VTP-200 Data Underwhelming: Analyst Weighs On Mixed Perspectives

Explore the latest findings from Barinthus Biotherapeutics on VTP-200's performance in the APOLLO trial for low-grade cervical lesions linked to persistent hrHPV infection. Positive trends were noted, though not statistically significant. No major safety concerns were observed.

Vandana Singh

Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates

Synlogic, Inc. (NASDAQ: SYBX) came out with a quarterly loss of $1.71 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $3.60 per share a year ago. These figures are adjusted for non-recurring items.

Zacks

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-26.43M

Investing Cash Flow (TTM)

569.00K

Financing Cash Flow (TTM)

0

Free Cash Flow (TTM)

-26.43M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-25.86M

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

-$24.49M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

0.43

Earnings Yield % (TTM)

-170.03%

Earnings Yield % (FWD)

-151.69%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.40

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$59.30M

Debt to Equity

0.18

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$0.59

Close

-

Volume / Avg.

251.00 / 75.64K

Day Range

$0.59 - $0.59

52 Wk Range

0.51 - 1.83

Market Cap

$24.10M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

45

Short Interest

0.18%

Days to Cover

1.82

About

Sector

Health Care

Industry

Biotechnology

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietar...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Barinthus Biotherapeutics (BRNS) stock?

A

You can purchase shares of Barinthus Biotherapeutics (NASDAQ:BRNS) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Barinthus Biotherapeutics (BRNS) competitors?

A

Other companies in Barinthus Biotherapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Barinthus Biotherapeutics (BRNS) stock?

A

Barinthus Biotherapeutics has a consensus price target of $5.50.

Q

What is the current price for Barinthus Biotherapeutics (BRNS)?

A

The stock price for Barinthus Biotherapeutics (NASDAQ: BRNS) is $0.59 last updated August 13, 2026 at 5:04 AM EDT.

Q

Does Barinthus Biotherapeutics (BRNS) pay a dividend?

A

There are no upcoming dividends for Barinthus Biotherapeutics.

Q

When is Barinthus Biotherapeutics (NASDAQ:BRNS) reporting earnings?

A

Barinthus Biotherapeutics does not have any upcoming earnings scheduled.

Q

Is Barinthus Biotherapeutics (BRNS) going to split?

A

There is no upcoming split for Barinthus Biotherapeutics.

Q

What sector and industry does Barinthus Biotherapeutics (BRNS) operate in?

A

Barinthus Biotherapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.